Humacyl Acellular VesselMay 1, 2019
Humacyl is an off-the-shelf bioengineered human acellular vessel proposed for use as a hemodialysis access graft in patients with end stage renal disease (ESRD). This technology uses a process to decellularize donated human vascular smooth muscle cells, while preserving extracellular matrix proteins. This results in a tubular scaffold that is acellular at the time of implantation and becomes populated with the patient’s cells.
If you have a Hayes login, click here to view the full report on the Knowledge Center.